The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.
 
Lakshmi Nayak
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Timothy Smith
No Relationships to Disclose
 
Sarah C. Gaffey
No Relationships to Disclose
 
Katherine B. Peters
Consulting or Advisory Role - Abbvie; Agios; Novocure
Research Funding - Abbvie; Agios; BioMimetix; Eisai; Genentech; Merck; VBL Therapeutics
 
Jennifer Leigh Clarke
Research Funding - Agios (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Agios
 
Justin T Jordan
Patents, Royalties, Other Intellectual Property - textbook royalties
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; Boston Biomedical; CarThera; Celldex; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Merck; Novogen; Omniox; Oxigene; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
 
Phioanh Leia Nghiemphu
Consulting or Advisory Role - Abbvie; Novocure
Research Funding - Genentech/Roche; Novartis
 
Thomas Joseph Kaley
No Relationships to Disclose
 
Howard Colman
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Abbvie; Genentech; Insys Therapeutics; Novocure; Omniox; Roche
Research Funding - Abbvie; BeiGene; DNAtrix; Kadmon; Merck; Newlink Genetics; Orbus Therapeutics; Plexxikon
 
Terri Armstrong
No Relationships to Disclose
 
Martin J. Taphoorn
No Relationships to Disclose
 
Victoria Caruso
No Relationships to Disclose
 
Myriam Bednarek Debruyne
No Relationships to Disclose
 
Chinmay Bhavsar
No Relationships to Disclose
 
Annette M Molinaro
No Relationships to Disclose
 
Mariano Severgnini
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; AstraZeneca; Aurora Biopharma; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; Kadmon; Karyopharm Therapeutics; Lilly; Monteris Medical; Vascular Biogenics; Vivus; ZIOPHARM Oncology
Speakers' Bureau - Merck
Research Funding - Abbvie (Inst); Agios (Inst); Angiochem (Inst); ARIAD (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); ImmunoCellular Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly; Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Sanofi (Inst); Vascular Biogenics (Inst)
 
David A. Reardon
Honoraria - Abbvie; Bristol-Myers Squibb; Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Midatech Pharma (Inst); Tragara (Inst)